Atherosclerotic heart disease (AHD) is a major cause of morbidity and mortality worldwide.
Lowering low-density lipoprotein cholesterol (LDL-C) levels is a key strategy to prevent and …

Objective Multiple systematic reviews (SR) have been performed on the effects of proprotein
convertase subtilisin/kexin type 9 inhibitors (PCSK9i), often providing conflicting findings …

Inclisiran increases the number of low‐density lipoprotein surface receptors expressed on
hepatocytes using small interfering RNA directed against proprotein convertase …

Dyslipidemia and hypercholesterolemia are global health issues that require urgent and
efficient treatments due to their major impact on cardiovascular disease. The incidence of …

This is a 2-part series designed to provide front-line pharmacists with knowledge of how to
use antihyperlipidemic drugs to reduce low-density lipoprotein (LDL) Read part 1 here.The …